# Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

> **NCT00722046** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 198 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **BIOLOGICAL:** PF-04360365 0.1 mg/kg
- **BIOLOGICAL:** PF-04360365 0.5 mg/kg
- **BIOLOGICAL:** PF-04360365 1 mg/kg
- **DRUG:** Placebo
- **BIOLOGICAL:** PF-04360365 3 mg/kg
- **BIOLOGICAL:** PF-04360365 8.5 mg/kg

## Key facts

- **NCT ID:** NCT00722046
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-05
- **Primary completion:** 2011-08-16
- **Final completion:** 2011-08-16
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2022-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00722046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00722046, "Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00722046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*